Literature DB >> 8357328

Ventricular remodeling after myocardial infarction. Experimental and clinical studies.

G Ertl1, P Gaudron, K Hu.   

Abstract

Changes of ischemic myocardium following coronary occlusion, including active and passive functions, and adaptive changes of non-ischemic surviving myocardium have been summarized under the term "left ventricular remodeling" post myocardial infarction. An increase in left ventricular volume may be a consequence, and associated with an adverse prognosis. Although left ventricular dilatation may increase stroke volume and, thus, be compensatory at first, in about one-fifth of patients it ultimately results in progressive dysfunction and heart failure. Major determinants of this process are time, infarct size, infarct location, global left ventricular function assessed 4 days after infarction by radionuclide ejection fraction and right heart catheter (stroke volume), and morphology of the infarct-associated coronary artery. The surviving myocardium hypertrophies and may also dilate structurally. Depression of left ventricular ejection fraction chronically after the infarct is due to deterioration of wall motion of chamber segments initially classified normal by radionuclide analysis. Biochemical changes may also occur, including reduction of phosphocreatine, prolongation of time to peak Cai2+, and changes in myosin isoforms. Systemic or local humoral factors may be involved in these changes, however, clear evidence is still lacking. Perfusion of surviving myocardium may be altered under various conditions due to morphologic and functional changes of coronary vasculature. Successful prevention of heart failure and death by angiotensin converting enzyme inhibitors in asymptomatic patients with left ventricular dysfunction post-myocardial infarction has supported the pathophysiologic concepts of remodeling.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8357328     DOI: 10.1007/978-3-642-72497-8_9

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  6 in total

Review 1.  Angiotensin converting enzyme inhibitors in angina and myocardial infarction. What role will they play in the 1990s?

Authors:  G Ertl
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

2.  COMPARE-AMI trial: comparison of intracoronary injection of CD133+ bone marrow stem cells to placebo in patients after acute myocardial infarction and left ventricular dysfunction: study rationale and design.

Authors:  Samer Mansour; Denis-Claude Roy; Vincent Bouchard; Ba Khoi Nguyen; Louis Mathieu Stevens; Francois Gobeil; Alain Rivard; Guy Leclerc; François Reeves; Nicolas Noiseux
Journal:  J Cardiovasc Transl Res       Date:  2009-11-12       Impact factor: 4.132

3.  Immediate-early gene induction and MAP kinase activation during recovery from metabolic inhibition in cultured cardiac myocytes.

Authors:  A Yao; T Takahashi; T Aoyagi; K Kinugawa; O Kohmoto; S Sugiura; T Serizawa
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

Review 4.  The therapeutic potential of stem cells in heart disease.

Authors:  B E Strauer; M Brehm; C M Schannwell
Journal:  Cell Prolif       Date:  2008-02       Impact factor: 6.831

5.  Xinfuli Granule improves post-myocardial infarction ventricular remodeling and myocardial fibrosis in rats by regulating TGF-β/Smads signaling pathway.

Authors:  Jie Ma; Zhi-Yuan Li; Xiao-Peng Liang; Cai-Xia Guo; Pei-Pei Lu; Li-Hong Ma
Journal:  J Geriatr Cardiol       Date:  2017-05       Impact factor: 3.327

6.  The protective effect of isosteviol sodium on cardiac function and myocardial remodelling in transverse aortic constriction rat.

Authors:  Qingjin Ke; Fei Liu; Yuxin Tang; Jiedi Chen; Hui Hu; Xiaoou Sun; Wen Tan
Journal:  J Cell Mol Med       Date:  2020-12-17       Impact factor: 5.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.